Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 727Glioblastoma 354Gliosarcoma 341Brain Neoplasms 254Central Nervous System Neoplasms 223Astrocytoma 204Osteosarcoma 202Gastrointestinal Stromal Tumors 176Dendritic Cell Sarcoma, Interdigitating 174Glioma 165Lymphoma 163Burkitt Lymphoma 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 158Neoplasms 155Lymphoma, Non-Hodgkin 151Oligodendroglioma 147Recurrence 138Lymphoma, Large B-Cell, Diffuse 133Neuroblastoma 130Lymphoma, Follicular 127Breast Neoplasms 121Leukemia, Lymphocytic, Chronic, B-Cell 120Lymphoma, Mantle-Cell 119Leukemia 116Lymphoma, B-Cell, Marginal Zone 113Lymphoma, Large-Cell, Immunoblastic 112Rhabdomyosarcoma 111Hodgkin Disease 110Bone Neoplasms 109Sarcoma, Kaposi 102

Interventions

NVP-BKM120 1Imatinib Mesylate 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × 3rd Line GIST × Sarcoma × Clear all
NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
60 enrolled
Sarcoma

3rd Line GIST

NCT01735968 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
56 enrolled
Sarcoma

3rd Line GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡